Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Home Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update

/ Publications

Share the Post

About the Author

Related Posts

Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Read More
Scott Giacobello, CPA
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Management of adverse events in the AMPECT trial of nab-sirolimus for the treatment of advanced malignant perivascular epithelioid cell neoplasm (PEComa)
Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology

Comments

Comments are closed.